Evidence map›Paper›PMID 41993073›Full record

ArticleGlomerular diseases

Health Care Resource Utilization and Productivity Impairment in Adults with Immunoglobulin A Nephropathy: A Real-World, Observational, Global Analysis.

Sydney C W Tang, Dario Roccatello, Carolina Aldworth, Briana Ndife, Suparna Mallik, Aneesh Thomas George, Julia Kattlun, Mark Pletscher, Ceri Hirst, Michel Anton Kroes and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sydney C W TangDivision of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong SAR.
Dario RoccatelloDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Carolina AldworthUS Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Briana NdifeUS Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Suparna MallikGlobal Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Aneesh Thomas GeorgeValue and Access International, Novartis Healthcare Pvt. Ltd., Hyderabad, India.
Julia KattlunGlobal Program Management, Development, Novartis Pharma AG, Basel, Switzerland.
Mark PletscherValue and Access International, Novartis Pharma AG, Basel, Switzerland.
Ceri HirstGlobal Medical Affairs, Novartis Pharmaceuticals UK Ltd., London, UK.
Michel Anton KroesValue and Access International, Novartis Pharma AG, Basel, Switzerland.
Jade Garratt-WheeldonRare Diseases Franchise, Adelphi Real World, Bollington, UK.
Emma ChattertonRare Diseases Franchise, Adelphi Real World, Bollington, UK.
Jonathan de CourcyRare Diseases Franchise, Adelphi Real World, Bollington, UK.
Richard A LafayetteDivision of Nephrology, Stanford Glomerular Disease Center, Stanford University, Stanford, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: There are limited data characterizing the health care resource utilization (HCRU) associated with immunoglobulin A nephropathy (IgAN) and its burden on patients and health care systems. Here, we describe the impact of IgAN on HCRU and productivity using nephrologist- and patient-reported data collected across distinct global geographic regions. Methods: This was a retrospective, cross-sectional survey of nephrologists managing patients with IgAN ( Results: At survey completion, mean (± standard deviation [SD]) patient age was 43.6 (±15.0) years and 58.7% of patients were male. Mean (±SD) estimated glomerular filtration rate was 67.6 (±30.7) mL/min/1.73 m Conclusion: The diagnosis and management of IgAN are associated with a substantial impact on HCRU and productivity across distinct regions. This highlights the unmet need for novel therapies that target the underlying disease pathophysiology to reduce the ongoing HCRU and humanistic burden associated with IgAN.

Indexed as

Diagnostic testingHealth care resource utilizationImmunoglobulin A nephropathyManagementPatient-reported outcomes

Identifiers

PMID41993073
PMCPMC13082774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.